Neurophet is a neurotechnology company developing software that applies artificial intelligence to the analysis of brain MRI data. The company focuses on automated quantification of structural brain changes to support earlier and more objective assessment of neurological disorders.

Its platform uses machine learning algorithms to segment brain regions, measure volumetric changes, and extract imaging biomarkers associated with conditions such as Alzheimer’s disease and Parkinson’s disease. The software is designed to standardize image interpretation and integrate into existing radiology and clinical workflows.

Neurophet’s technology is used in hospitals, research institutions, and pharmaceutical clinical trials to support diagnosis, disease monitoring, and drug development. The company positions its platform as neuroimaging analytics infrastructure that complements clinical decision-making rather than a standalone imaging modality.